Arnfin Bergmann

1.8k total citations
30 papers, 310 citations indexed

About

Arnfin Bergmann is a scholar working on Pathology and Forensic Medicine, Psychiatry and Mental health and Neurology. According to data from OpenAlex, Arnfin Bergmann has authored 30 papers receiving a total of 310 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 5 papers in Psychiatry and Mental health and 4 papers in Neurology. Recurrent topics in Arnfin Bergmann's work include Multiple Sclerosis Research Studies (17 papers), Epilepsy research and treatment (4 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Arnfin Bergmann is often cited by papers focused on Multiple Sclerosis Research Studies (17 papers), Epilepsy research and treatment (4 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Arnfin Bergmann collaborates with scholars based in Germany, Switzerland and United States. Arnfin Bergmann's co-authors include Stefan Braune, Michael Lang, Stefan Braune, Robert Hyde, Fabio Pellegrini, Ulrich Freudensprung, Thomas H. Mosley, Christian Bischoff, Iftikhar J. Kullo and Herbert Schreiber and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and SLEEP.

In The Last Decade

Arnfin Bergmann

28 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arnfin Bergmann Germany 10 161 59 51 47 39 30 310
Joyce Pauline Joseph Malaysia 10 241 1.5× 54 0.9× 96 1.9× 50 1.1× 92 2.4× 24 408
Madalina Chirieac United States 7 277 1.7× 59 1.0× 105 2.1× 21 0.4× 73 1.9× 12 504
Jessica B. Smith United States 12 247 1.5× 22 0.4× 67 1.3× 28 0.6× 23 0.6× 18 465
Marguerite Duggan Ireland 11 285 1.8× 52 0.9× 39 0.8× 9 0.2× 60 1.5× 14 350
L. G. F. Sinnige Netherlands 9 78 0.5× 17 0.3× 22 0.4× 13 0.3× 28 0.7× 14 209
José M.A. Wijnands Canada 14 418 2.6× 64 1.1× 47 0.9× 8 0.2× 152 3.9× 25 612
Yoshiyuki Shibasaki Japan 10 59 0.4× 75 1.3× 18 0.4× 8 0.2× 37 0.9× 25 281
Michael Haboubi Canada 2 433 2.7× 29 0.5× 121 2.4× 6 0.1× 89 2.3× 3 501
Jonathan Hosey United States 3 433 2.7× 28 0.5× 121 2.4× 6 0.1× 89 2.3× 5 505
Tejaswi Kandula Australia 8 21 0.1× 36 0.6× 147 2.9× 91 1.9× 17 0.4× 21 438

Countries citing papers authored by Arnfin Bergmann

Since Specialization
Citations

This map shows the geographic impact of Arnfin Bergmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnfin Bergmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnfin Bergmann more than expected).

Fields of papers citing papers by Arnfin Bergmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnfin Bergmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnfin Bergmann. The network helps show where Arnfin Bergmann may publish in the future.

Co-authorship network of co-authors of Arnfin Bergmann

This figure shows the co-authorship network connecting the top 25 collaborators of Arnfin Bergmann. A scholar is included among the top collaborators of Arnfin Bergmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnfin Bergmann. Arnfin Bergmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rouzic, Erwan Muros‐Le, Stefan Braune, Arnfin Bergmann, et al.. (2024). Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments. SHILAP Revista de lepidopterología. 16. 2699787795–2699787795. 1 indexed citations
2.
Bergmann, Arnfin, et al.. (2023). Erkrankte mit DiGA nicht alleine lassen. NeuroTransmitter. 34(5). 16–18.
3.
Braune, Stefan, et al.. (2022). PHREND®—A Real-World Data-Driven Tool Supporting Clinical Decisions to Optimize Treatment in Relapsing-Remitting Multiple Sclerosis. Frontiers in Digital Health. 4. 856829–856829. 3 indexed citations
4.
Bergmann, Arnfin, et al.. (2021). Development of Registry Data to Create Interactive Doctor-Patient Platforms for Personalized Patient Care, Taking the Example of the DESTINY System. Frontiers in Digital Health. 3. 633427–633427. 8 indexed citations
5.
6.
Braune, Stefan, et al.. (2020). Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis. BMC Medical Research Methodology. 20(1). 24–24. 22 indexed citations
7.
König, Carl Heinz Wirsing von, Christoph Maas, Wolfgang Greiner, et al.. (2019). PND48 BURDEN OF MULTIPLE SCLEROSIS IN GERMANY — A MATCHED COHORT STUDY USING A LARGE CLAIMS DATABASE. Value in Health. 22. S745–S745.
8.
9.
Braune, Stefan, et al.. (2018). Supporting personalized treatment decisions in relapsing remitting multiple sclerosis (RRMS) (P6.358). Neurology. 90(15_supplement). 1 indexed citations
10.
11.
Braune, Stefan, et al.. (2015). Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis. Journal of Neurology. 263(2). 327–333. 22 indexed citations
12.
Bergmann, Arnfin, et al.. (2013). Patient Preferences in the Choice of Disease Modifying Drugs for Multiple Sclerosis. Value in Health. 16(7). A595–A596. 1 indexed citations
13.
Braune, Stefan, et al.. (2013). Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort. Journal of Neurology. 260(12). 2981–2985. 37 indexed citations
14.
Schreiber, Herbert, Michael Lang, Tatjana Fischer, et al.. (2013). Longitudinal Observation of Attentional and Fronto-Temporal Cognitive Functions in Relapsing-Remitting Multiple Sclerosis (RRMS) – 6 Years Follow-Up (S10.003). Neurology. 80(7_supplement). 1 indexed citations
15.
Bischoff, Christian, Herbert Schreiber, & Arnfin Bergmann. (2012). Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment. Journal of Neurology. 259(11). 2347–2353. 11 indexed citations
16.
Lang, Michael, Peter Flachenecker, W. Hofmann, et al.. (2011). Fatigue, cognition and personality in patients with relapsing-remitting multiple sclerosis (RRMS) - A longitudinal study. Multiple Sclerosis Journal. 17(10). 2 indexed citations
17.
Cramer, Joyce A., et al.. (2010). Non-interventional surveillance study of adverse events in patients with epilepsy. Acta Neurologica Scandinavica. 124(1). 13–21. 24 indexed citations
18.
Saleem, Umer, NG Morgenthaler, S. T. Turner, et al.. (2009). Plasma Midregional Pro-atrial Natriuretic Peptide Is Associated With Blood Pressure Indices and Hypertension Severity in Adults With Hypertension. American Journal of Hypertension. 22(4). 425–431. 20 indexed citations
19.
Bauer, Jürgen, Arnfin Bergmann, Markus Reuber, Stefan Stodieck, & Pierre Genton. (2002). Tolerability of tiagabine: a prospective open‐label study. Epileptic Disorders. 4(4). 257–260. 8 indexed citations
20.
Jensenius, Mogens, et al.. (1995). [Extrapulmonary tuberculosis. An important differential diagnosis in immigrants with suspected malignancy].. PubMed. 115(27). 3365–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joyce Pauline Joseph Breakdown of academic impact, for papers by Madalina Chirieac Breakdown of academic impact, for papers by Jessica B. Smith Breakdown of academic impact, for papers by Marguerite Duggan Breakdown of academic impact, for papers by L. G. F. Sinnige Breakdown of academic impact, for papers by José M.A. Wijnands Breakdown of academic impact, for papers by Yoshiyuki Shibasaki Breakdown of academic impact, for papers by Michael Haboubi Breakdown of academic impact, for papers by Jonathan Hosey Breakdown of academic impact, for papers by Tejaswi Kandula
Rankless by CCL
2026